Sponsored Research Agreements |
6 Months Ended | |
|---|---|---|
Jun. 30, 2017 | ||
| Research and Development [Abstract] | ||
| Research, Development, and Computer Software Disclosure |
9. Sponsored Research Agreements Checkpoint Therapeutics, Inc. NeuPharma, Inc. Sponsored Research Agreement
In connection with its license agreement with NeuPharma, Inc. (“NeuPharma”), Checkpoint entered into a Sponsored Research Agreement with NeuPharma for certain research and development activities. Effective January 11, 2016, TGTX, a related party, agreed to assume all costs associated with this Sponsored Research Agreement and paid Checkpoint for all amounts previously paid by the Company. For the three months ended June 30, 2017 and 2016, approximately $0.2 million and $0.2 million, respectively, was recognized in revenue in connection with the Sponsored Research Agreement in the Condensed Consolidated Statements of Operations. For the six months ended June 30, 2017 and 2016, approximately $0.4 million and $0.5 million, respectively, was recognized in revenue in connection with the Sponsored Research Agreement in the Condensed Consolidated Statements of Operations.
Helocyte, Inc. PepVax and Triplex Clinical Research and Support Agreements
In March 2016, Helocyte entered into an Investigator-Initiated Clinical Research Support Agreement, as amended, with the COH, to support a Phase 2 clinical study of its PepVax immunotherapy for CMV control in allogeneic stem cell transplant recipients (“PepVax Research Agreement”). The Phase 2 study is additionally supported by grants from the National Institutes of Health/National Cancer Institute (“NCI”). In February 2016, Helocyte entered into an Investigator-Initiated Clinical Research Support Agreement, as amended, with the COH, to support a Phase 2 clinical study of its Triplex immunotherapy for CMV control in allogeneic stem cell transplant recipients (“Triplex Research Agreement”). For the three months ended June 30, 2017 and 2016, Helocyte incurred expense of $0.5 million and nil, related to the Triplex Research Agreement and nil related to their PepVax Research Agreement, recorded as research and development expense in the Company’s Condensed Consolidated Statements of Operations. For the six months ended June 30, 2017 and 2016, Helocyte incurred expense of $1.0 million and $1.0 million, related to the Triplex Research Agreement and $0.2 million and $1.0 million related to their PepVax Research Agreement, recorded as research and development expense in the Company’s Condensed Consolidated Statements of Operations. Pentamer Sponsored Research Agreement On May 1, 2017, Helocyte and COH entered in a Sponsored Research Agreement for preclinical studies in connection with the development of Pentatmer. In June 2017, Helocyte made an upfront payment of $1.5 million to fund the development plan, the payment was recorded as a prepayment on the Condensed Consolidated Balance Sheets. For the three and six months ended June 30, 2017, Helocyte recorded approximately $12,000 in research and development expenses in the Company’s Condensed Consolidated Statements of Operations. No such expense was incurred in 2016. Mustang Bio, Inc. In connection with Mustang’s license with COH for the development of CAR-T, Mustang entered into a Sponsored Research Agreement in which Mustang will fund continued research in the amount of $2.0 million per year, payable in four equal annual installments, until 2020. For the three months ended June 30, 2017 and 2016, Mustang incurred expense of $0.5 million and $0.5 million, respectively, recorded as research and development expense in the Company’s Condensed Consolidated Statements of Operations. For the six months ended June 30, 2017 and 2016, Mustang incurred expense of $1.0 million and $1.0 million, respectively, recorded as research and development expense in the Company’s Condensed Consolidated Statements of Operations. CD 123 Clinical Research Support Agreement On February 17, 2017, Mustang entered into a Clinical Research Support Agreement for CD123. Pursuant to the terms of this agreement Mustang made an upfront payment of approximately $20,000 and will contribute an additional $0.1 million per patient in connection with the on-going investigator initiated study. Further, Mustang agreed to fund approximately $0.2 million over three years pertaining to the clinical development of CD123. For the three and six months ended June 30, 2017 Mustang recorded approximately $22,000 and $0.6 million, respectively, in research and development expenses in the Company’s Condensed Consolidated Statements of Operations. IL - 13 Clinical Research Support Agreement
Also on February 17, 2017, Mustang entered into a Clinical Research Support Agreement for IL-13. Pursuant to the terms of this agreement Mustang made an upfront payment of approximately $10,000 and will contribute an additional $0.1 million per patient in connection with the on-going investigator initiated study. Further, Mustang agreed to fund approximately $0.2 million over three years pertaining to the clinical development of IL-13. For the three and six months ended June 30, 2017, Mustang recorded approximately $11,000 and $1.0 million, respectively, in research and development expenses in the Company’s Condensed Consolidated Statements of Operations. |